$1161.46
22.651.99%
Last update: 11:08 AM
15 minutes delayed
Comments
Loading...
Latest news for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock
Regeneron Pharmaceuticals Stock (NASDAQ: REGN)
Categories: All
Tuesday, September 17, 2024
Monday, September 16, 2024
Friday, September 13, 2024
Thursday, September 12, 2024
Wednesday, September 11, 2024
- Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
- Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
- Regeneron Pharmaceuticals Announced New Analy...
- Regeneron And Sanofi's Dupixent (Dupilumab) P...
- Regeneron And Sanofi's Dupixent Becomes First...
Tuesday, September 10, 2024
Monday, September 09, 2024
Thursday, September 05, 2024
Tuesday, August 27, 2024
Monday, August 26, 2024
Friday, August 23, 2024
Wednesday, August 21, 2024
Tuesday, August 20, 2024
Tuesday, August 13, 2024
Thursday, August 08, 2024
Friday, August 02, 2024
- JP Morgan Maintains Overweight on Regeneron P...
- RBC Capital Maintains Outperform on Regeneron...
- Guggenheim Maintains Buy on Regeneron Pharmac...
- Wells Fargo Maintains Overweight on Regeneron...
- Barclays Maintains Overweight on Regeneron Ph...
- Analyst Ratings For Regeneron Pharmaceuticals
- Truist Securities Reiterates Buy on Regeneron...
Thursday, August 01, 2024
- Regeneron Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
- Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
- US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
- Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
- Regeneron Pharmaceuticals Q2 2024 Adj EPS $11...